#targeted therapy — Thursday, January 22, 2026 (1 items)
| 0 | ℹ |
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
(nejm.org)
|
New England Journal of Medicine 2026-01-22 | #cancer #clinical trial #immunotherapy #targeted therapy |